Evoke Pharma Inc. (EVOK) |
|
3.64 0.03 (0.83%)
|
07-07 15:43 |
|
Open: |
3.59 |
Pre. Close: |
3.61 |
|
High:
|
3.64 |
Low:
|
3.46 |
|
Volume:
|
406,254 |
Market Cap:
|
90M |
|
|
|
|
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.792 - 3.812 |
3.812 - 3.826 |
|
Low:
|
3.467 - 3.487 |
3.487 - 3.501 |
|
Close:
|
3.579 - 3.612 |
3.612 - 3.637 |
|
Technical analysis |
as of: 2020-07-07 3:04:17 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 5.84 One year: 6.82 |
| Support: |
Support1: 3.21 Support2: 2.10 |
| Resistance: |
Resistance1: 5.00 Resistance2: 5.84 |
| Pivot: |
3.28  |
| Moving Average: |
MA(5): 3.60 MA(20): 3.06
MA(100): 1.76 MA(250): 1.40 |
| MACD: |
MACD(12,26): 0.40 Signal(9): 0.39 |
| Stochastic oscillator: |
%K(14,3): 51.19 %D(3): 51.58 |
| RSI: |
RSI(14): 64.75 |
| 52-week: |
High: 5.00 Low: 0.73 Change(%): 308.0 |
| Average Vol(K): |
3-Month: 157009 10-Days: 158807 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.EVOK has closed below upper band by 36.7%. Bollinger Bands are 194.3% wider than normal. The large width of the bands suggest high volatility as compared to EVOK's normal range. The bands have been in this wide range for 10 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 26 Jun 2020
Wall Street's Thoughts on Evoke Pharma Inc (EVOK) Stock - InvestorsObserver
Thu, 25 Jun 2020
Is Evoke Pharma Inc (EVOK) Stock a Good Value Thursday? - InvestorsObserver
Thu, 25 Jun 2020
Evoke Pharma Inc (NASDAQ:EVOK) Hits New High After the FDA Approval - Small Cap Exclusive
Tue, 23 Jun 2020
Evoke Pharma Inc. (NASDAQ:EVOK) Recent Earnings Shows Major Promise - The Oracle Dispatch
Tue, 23 Jun 2020
Evoke Pharma, Inc. (EVOK) Gains 512.90% in one Year: What’s Next? - The News Heater
Mon, 22 Jun 2020
Evoke Pharma +71% PM on FDA approval - Seeking Alpha
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ Capital Market |
| Sector: Healthcare |
| Industry: Drug ManufacturersSpecialty & Generic |
| Shares Out. (M) |
25 |
| Shares Float (M) |
22 |
|
% Held by Insiders
|
4.15 |
|
% Held by Institutions
|
14.52 |
|
Shares Short (K)
|
310 |
|
Shares Short P. Month (K)
|
123 |
Stock Financials |
|
EPS
|
-0.289 |
|
EPS Est This Year
|
-0.820 |
|
EPS Est Next Year
|
-0.170 |
|
Book Value (p.s.)
|
0.120 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-96.9 |
|
Return on Equity (ttm)
|
-231.8 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-5 |
|
Levered Free Cash Flow (M)
|
-3 |
Stock Valuations |
|
PE Ratio
|
-12.35 |
|
PEG Ratio
|
|
|
Price to Book value
|
29.75 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-16.36 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
